Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?
Sang‐Min Lee(Seoul National University), Koen van Besien(University Hospitals of Cleveland), Adrienne A. Phillips(Palmetto Hematology Oncology), Michael S. Samuel(Cancer Research UK Scotland Institute), Usama Gergis(Thomas Jefferson University Hospital), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Jingmei Hsu(Cancer Research Institute), Yassine Tahri(Université Libre de Bruxelles), Zhengming Chen(Cornell University), Melissa M. Cushing(NewYork–Presbyterian Hospital), Sebastian Mayer(Mount Sinai Hospital), Gail J. Roboz(Cornell University)
Cited by 1
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k